Peter J Weiden
Affiliation: State University of New York
- Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidonePeter J Weiden
Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
J Clin Psychopharmacol 23:595-600. 2003....
- EPS profiles: the atypical antipsychotics are not all the samePeter J Weiden
Dept of Psychiatry, SUNY Downstate Medical Center in Brooklyn, NY 11203, USA
J Psychiatr Pract 13:13-24. 2007..This review discusses differences among the SGAs in EPS liability, relationships between dosing and type of EPS, and situations in which differences in EPS liability among the SGAs are clinically relevant...
- Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyDiana O Perkins
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
J Clin Psychiatry 69:106-13. 2008..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
- A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trialStephen M Stahl
Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
J Clin Psychopharmacol 30:425-30. 2010....
- Iloperidone for the treatment of schizophrenia: an updated clinical reviewPeter J Weiden
Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612 7327, USA
Clin Schizophr Relat Psychoses 6:34-44. 2012..This review is a comprehensive synthesis of the history and clinical trials data leading up to approval, and evaluates iloperidone within the clinical context of how it compares with other available antipsychotics...
- Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of SchizophreniaHenry A Nasrallah
Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
J Clin Psychiatry 70:4-46. 2009..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
- Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidonePeter J Weiden
Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
Neuropsychopharmacology 33:985-94. 2008..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
- A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcomePeter J Weiden
Center for Cognitive Medicine, Department of Psychiatry, University of Illinois, Chicago, IL 60612, USA
J Clin Psychiatry 70:1397-406. 2009..We report on acceptance and initial adherence outcomes with risperidone long-acting injection (RLAI) in first-episode schizophrenia patients...
- Understanding and treating "first-episode" schizophreniaPeter J Weiden
Department of Psychiatry, University of Illinois Medical Center, Chicago, IL, USA
Psychiatr Clin North Am 30:481-510. 2007..Clinicians and treatment services should try to identify "first-episode" patients in time to be able to anticipate and address these issues...
- Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophreniaPeter J Weiden
Department of Psychiatry, SUNY Downstate Medical Center State, Brooklyn, NY 11203, USA
J Clin Psychiatry 64:580-8. 2003....
- The art and science of switching of antipsychotic medications, part 1Peter J Weiden
Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center, Brooklyn, USA
J Clin Psychiatry 67:e15. 2006....
- Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episodeDiana O Perkins
Department of Psychiatry, C.B.# 7160, University of North Carolina School of Medicine, Chapel Hill, 27599-7160, USA
Schizophr Res 83:53-63. 2006....
- Understanding and addressing adherence issues in schizophrenia: from theory to practicePeter J Weiden
Center for Cognitive Medicine, Department of Psychiatry, University of Illinois, Chicago 60612, USA
J Clin Psychiatry 68:14-9. 2007..5) Adherence behavior changes and fluctuates over time and should be considered as part of the illness in the context of the long-term trajectory of desired clinical outcomes such as recovery...
- Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculumPeter J Weiden
Schizophrenia Research Service, SUNY Downstate Medical Center, 450 Clarkson Ave, Brooklyn, New York 11203, USA
Acad Psychiatry 29:203-10. 2005..The objective of this article is to increase awareness about this vagueness among academic psychiatrists and to offer a suggested curriculum to facilitate implementation...
- Switching in the era of atypical antipsychotics. An updated reviewPeter J Weiden
Department of Psychiatry, State University of New York, Downstate Medical Center Brooklyn, NY 11203, USA
Postgrad Med . 2006....
- Obesity as a risk factor for antipsychotic noncompliancePeter J Weiden
SUNY Health Sciences Center at Brooklyn, Brooklyn, NY 11203 2098, USA
Schizophr Res 66:51-7. 2004..It is, therefore, increasingly important to understand the impact of obesity and perceived weight problems on compliance with these medications...
- Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trialPeter J Weiden
Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn 11203, USA
J Clin Psychiatry 68:12-9. 2007..Therefore, the clinical implications of the CATIE phase 1 findings may depend, in part, on the underlying assumptions of the ACD outcome measure...
- Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medicationsPeter J Weiden
Department of Psychiatry, State University of New York SUNY Downstate Medical Center, Brooklyn, NY, USA
J Clin Psychiatry 68:14-23. 2007..The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient...
- Switching antipsychotics: an updated review with a focus on quetiapinePeter J Weiden
Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
J Psychopharmacol 20:104-18. 2006..Finally, advice is provided on the assessments necessary when evaluating the success of a change in therapy, together with guidance on the optimal duration of treatment trials...
- Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemiaPeter J Weiden
State University of New York SUNY Downstate Medical Center and King s County Hospital, Brooklyn, N Y, USA
J Clin Psychiatry 68:34-9. 2007....
- The art and science of switching antipsychotic medications, part 2Peter J Weiden
Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, USA
J Clin Psychiatry 68:e02. 2007....
- Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medicationsPatricia L Scheifler
Partnership for Recovery, Sylacauga, AL 35150, USA
Postgrad Med . 2006..It is also important to revisit the initial treatment goals to distinguish primary pharmacologic improvements from secondary psychologic reactions and challenges arising from those improvements...
- Partial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPeter J Weiden
State University of New York in Brooklyn, USA
Psychiatr Serv 55:886-91. 2004..96. CONCLUSIONS: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior...
- Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorderGeorge M Simpson
Department of Psychiatry and the Behavioral Sciences, LAC USC Medical Center, IRD RM 204, Psychiatric Outpatient Clinic, 2020 Zonal Ave, Los Angeles, CA 90033, USA
Am J Psychiatry 161:1837-47. 2004..The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder...
- Antipsychotic-induced movement disorders - forgotten but not gonePeter J Weiden
Acta Psychiatr Scand 117:401-2. 2008
- Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophreniaAndrew J Cutler
University of Florida, Gainesville, FL, USA
J Clin Psychopharmacol 28:S20-8. 2008..Overall, there was improvement in akathisia with iloperidone treatment. Iloperidone treatment was effective, safe, and well tolerated in patients with acute exacerbation of schizophrenia...
- Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trialsPeter J Weiden
Center for Cognitive Medicine, Chicago, IL 60612, USA
J Clin Psychopharmacol 28:S12-9. 2008....
- Cognitive behavior therapy for schizophreniaDouglas Turkington
Department of Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear NE4 4LP, UK
Am J Psychiatry 163:365-73. 2006..The objective of this article is to offer a broad perspective on the subject of cognitive behavior therapy for schizophrenia for the American reader...
- From clinical research to clinical practice: a 4-year review of ziprasidoneCharles B Nemeroff
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
CNS Spectr 10:1-20. 2005..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
- Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioningDavid L Ginsberg
Georgetown University School of Medicine, USA
CNS Spectr 10:1-13; discussion 14-15. 2005..Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments...
- Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a RoadmapPeter J Weiden
University of Illinois at Chicago, USA
J Clin Psychiatry 68:1-48. 2007....
- Distress with medication side effects among persons with severe mental illnessNancy H Covell
Division of Health Services Research, Mount Sinai School of Medicine, New York, NY, USA
Adm Policy Ment Health 34:435-42. 2007..The most distressing SEs reported were embarrassment from weight gain, weight gain, dry mouth, and sedation. The likelihood of distress by particular SEs varied by gender and race...